公开(公告)号：US20170157104A1

公开(公告)日：2017-06-08

申请号：US15431069

申请日：2017-02-13

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/454 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/422 ,  A61K31/438 ,  A61K31/4178 ,  A61K31/695 ,  A61K31/496 ,  A61K31/506 ,  A61K31/4418 ,  A61K31/5377 ,  A61K31/4355 ,  A61K45/06 ,  A61K31/4545

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US09586978B2

公开(公告)日：2017-03-07

申请号：US14558318

申请日：2014-12-02

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K38/00 ,  C07K16/00 ,  C07F7/02 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

公开(公告)号：US20140315792A1

公开(公告)日：2014-10-23

申请号：US14180886

申请日：2014-02-14

Applicant: AbbVie, Inc.

Inventor： Rolf Wagner ,  John K. Pratt ,  Dachun Liu ,  Michael D. Tufano ,  David A. DeGoey ,  Warren M. Kati ,  Charles W. Hutchins ,  Pamela L. Dooner ,  John T. Randolph ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  Mark A. Matulenko ,  Ryan G. Keddy ,  Tammie K. Jinkerson ,  Todd W. Rockway ,  Clarence J. Maring ,  Douglas K. Hutchinson ,  Charles A. Flentge ,  David A. Betebenner ,  Kathy Sarris ,  Kevin R. Woller ,  Seble H. Wagaw ,  Jean C. Califano ,  Wenke Li ,  Daniel D. Caspi ,  Mary E. Bellizzi ,  Yi Gao ,  Allan C. Krueger

IPC: C07K5/06 ,  C07D417/14 ,  C07C33/26 ,  C07D403/14 ,  C07C205/19

CPC classification number: C07F9/65583 ,  C07C33/26 ,  C07C201/06 ,  C07C205/19 ,  C07D207/08 ,  C07D207/09 ,  C07D207/16 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D471/04 ,  C07D491/113 ,  C07K5/06

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20190015402A1

公开(公告)日：2019-01-17

申请号：US16042447

申请日：2018-07-23

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/454 ,  A61K31/4418 ,  C07D401/14 ,  A61K45/06 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K31/435 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4178 ,  C07F7/02 ,  C07D491/113 ,  C07D453/00 ,  C07D417/14 ,  C07D413/14 ,  C07D405/14 ,  C07D403/14 ,  A61K31/4439

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US10039754B2

公开(公告)日：2018-08-07

申请号：US15431069

申请日：2017-02-13

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K38/00 ,  A61K31/454 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/422 ,  A61K31/438 ,  A61K31/4545 ,  A61K31/695 ,  A61K31/496 ,  A61K31/506 ,  A61K31/4418 ,  A61K31/5377 ,  A61K31/4355 ,  A61K31/4178

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20230285378A1

公开(公告)日：2023-09-14

申请号：US17941090

申请日：2022-09-09

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Warren M. Kati ,  Tammie K. Jinkerson ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/454 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07D403/14 ,  C07F7/02 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  A61K31/435

CPC classification number: A61K31/454 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07D403/14 ,  C07F7/02 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  A61K31/435 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20170157105A1

公开(公告)日：2017-06-08

申请号：US15434789

申请日：2017-02-16

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/695

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US08969325B2

公开(公告)日：2015-03-03

申请号：US13716862

申请日：2012-12-17

Applicant: AbbVie Inc.

Inventor： Michael J. Dart ,  Philip R. Kym ,  Eric A. Voight ,  Anurupa Shrestha ,  Jerome F. Daanen ,  Tammie K. Jinkerson ,  Ryan G. Keddy ,  Sridhar Peddi ,  Arthur Gomtsyan ,  Michael E. Kort ,  Gregory A. Gfesser ,  Kevin R. Woller ,  Derek W. Nelson

IPC: C07D405/12 ,  C07D215/38 ,  C07D239/80 ,  C07D413/12 ,  C07D491/052 ,  A61K31/192 ,  A61K31/4704 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/538 ,  A61K45/06 ,  C07D413/14 ,  C07D215/227 ,  C07D265/36

CPC classification number: C07D405/12 ,  A61K31/192 ,  A61K31/4704 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/538 ,  A61K45/06 ,  C07D215/227 ,  C07D215/38 ,  C07D239/80 ,  C07D265/36 ,  C07D413/12 ,  C07D413/14 ,  C07D491/052

Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 本文公开了式（I）的化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，G，Z，A，m，n和p如说明书中所定义。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：US10028937B2

公开(公告)日：2018-07-24

申请号：US15434789

申请日：2017-02-16

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K38/00 ,  C07K16/00 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/4439 ,  A61K31/422 ,  A61K31/4418 ,  A61K31/4545 ,  A61K31/695 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/438 ,  A61K31/435

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US09163017B2

公开(公告)日：2015-10-20

申请号：US14021435

申请日：2013-09-09

Applicant: ABBVIE INC.

Inventor： David A. Degoey ,  Pamela L. Donner ,  Warren M. Kati ,  Charles W. Hutchins ,  Mark A. Matulenko ,  Tammie K. Jinkerson ,  Ryan G. Keddy

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。